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Abstract 
Background: Thalassaemia major (TM) patients need regular blood transfusions that lead to 
accumulation of iron and death from heart failure. Deferiprone has been reported to be superior to 
deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but 
little is known of their relative effects on the right ventricle (RV), which is being increasingly 
recognised as an important prognostic factor in cardiomyopathy. Therefore data from a prospective 
randomised controlled trial (RCT) comparing these chelators was retrospectively analysed to assess 
the RV responses to these drugs.  
Methods: In the RCT, 61 TM patients were randomised to receive either deferiprone or deferoxamine 
monotherapy, and CMR scans for T2* and cardiac function were obtained. Data were re-analysed for 
RV volumes and function at baseline, and after 6 and 12 months of treatment.  
 Results:  From baseline to 12 months, deferiprone reduced RV end systolic volume (ESV) from 37.7 
to 34.2 mL (p=0.009), whilst RV ejection fraction (EF) increased from 69.9 to 72.2% (p=0.001). This 
was associated with a 27% increase in T2* (p<0.001) and 3.1% increase in LVEF (p<0.001). By 
contrast, deferoxamine showed no change in RVESV (38.1 to 39.1mL, p=0.38), or RVEF (70.0 to 
69.9%, p=0.93) whereas the T2* increased by 13% (p<0.001), but with no change in LVEF (0.32%; 
p=0.66). Analysis of between drugs treatment effects, showed significant improvements favouring 
deferiprone with a mean effect on RVESV of -1.82mL (p=0.014) and 1.16% for RVEF (p=0.008). 
Using regression analysis the improvement in RVEF at 12 months was shown to be greater in patients 
with lower baseline EF values (p<0.001), with a significant difference in RVEF of 3.5% favouring 
deferiprone over deferoxamine (p=0.012).  
Conclusion: In this retrospective analysis of a prospective RCT, deferiprone monotherapy was 
superior to deferoxamine for improvement in RVEF and end-systolic volume. This improvement in 
the RV volumes and function may contribute to the improved cardiac outcomes seen with deferiprone. 
Introduction 
Blood transfusions are standard therapy for patients with β-thalassaemia major (TM) and prevent 
death in childhood, but although clinical status and short term survival improve, each unit of blood 
contains about 200-250mg of iron which the body cannot eliminate, which leads to long term iron 
accumulation. Patients treated only with blood transfusions may die in the second and third decades of 
life from the complications of iron overload, in particular heart failure.[1,2]  Myocyte damage is 
related to the production of reactive oxygen species (ROS) formed as levels of labile iron rise, which 
cause oxidative damage to membranes and mitochondrial respiratory chain enzyme dysfunction.[3,4] 
Chelation therapy can reduce tissue iron levels and the incidence of cardiac complications, but 
patients at risk need to be accurately profiled for appropriate treatment. The cardiovascular magnetic 
resonance (CMR) relaxation parameter T2* is sensitive to storage tissue iron in haemosiderin because 
of the creation of field inhomogeneities by iron particles, and the clinical adoption of this technique is 
now widespread as a mainstay of cardiac iron overload assessment and treatment,[5,6,7] with 
important capability to predict future cardiac events,[8] and evidence of significant beneficial effects 
on cardiac mortality.[9] 
Deferoxamine was the first iron chelating agent for clinical use and became standard therapy in the 
1970s. It is a large positively charged lipophobic molecule, is poorly absorbed by the digestive system 
and has a short plasma half life.[10,11] It is therefore administered subcutaneously using a portable 
syringe system usually overnight typically 5 times per week. This therapy can be very problematic 
with poor compliance, and a number of factors result in long-term cardiac iron accumulation with its 
use.[12] The second clinical iron chelator was deferiprone, which is a much smaller neutrally charged 
lipophilic molecule which allows good gastrointestinal absorption and cellular access.[10,11] The 
plasma half life is longer allowing oral administration with three doses per day. Direct comparison 
trials show that deferiprone has greater efficacy than deferoxamine for reducing myocardial iron 
loading and improving left ventricular (LV) systolic function.[13,14] However, there is a paucity of 
data related to the effects of these chelators on the right ventricle (RV), which is known to be an 
important independent predictor of outcome in dilated cardiomyopathy,[15] and ischaemic heart 
disease.[16,17,18] Recent papers have established the normal ranges for RV volumetric parameters 
for non-iron loaded TM patients and shown a significant relation between T2* and RV ejection 
fraction (RVEF), including a small percentage of patients with impaired RVEF but normal 
LVEF.[19,20]  In order to identify and compare the effects of deferiprone and deferoxamine, we 
reanalyzed the CMR images for the LA16 trial, which was a randomized controlled trial (RCT) 
comparing the 2 drugs.[14] Our hypothesis was that deferiprone would improve RV function more 
than deferoxamine.  
 
Methods 
The LA16 RCT consisted of 61 regularly transfused patients with TM from 4 centres in Greece and 
Italy.[14] All patients were previously treated with subcutaneous deferoxamine monotherapy. 
Inclusion criteria included a T2* between 8 and 20ms and LVEF greater than 56% based on the lower 
normal limit for non-anaemic subjects from previously published data.[21] No patient had heart 
failure symptoms. Deferiprone was allocated to 29 patients (actual dose 92mg/kg daily) whilst 32 
patients were allocated to continue with deferoxamine therapy (dose of 43mg/kg/day overnight for an 
average of 5.7 days per week). Written informed consent was obtained according to local ethics 
committee approval. 
 
Iron loading and cardiac function was assessed using CMR. The T2* sequences were installed at the 
local CMR facilities, Athens (GE CVi) and Cagliari (GE Signa). The technique was validated by 
scanning phantoms of known T2* and testing intra-site reproducibility by scanning 5 patients twice at 
the local centre. The same patients were scanned at the reference site in London (Siemens Sonata) for 
inter-site reproducibility.  A coefficient of variation (CV) ≤15% was defined as acceptable. Site inter-
study variability was 2.4% for Cagliari and 3.5% for Athens. Comparison with the reference site 
yielded CVs of 1.6% and 9.7% respectively. Volumetric data were acquired using a steady state free 
precession sequence (FIESTA). A set of contiguous short axis cines were acquired to give complete 
coverage of both ventricles. Care was taken to place the basal slice parallel to the atrioventricular 
groove. Slice thickness was 8mm with a spacing of 10mm.  No patient had a history of, and no CMR 
scan showed any features of pulmonary hypertension (normal pulmonary artery size, no right 
ventricular hypertrophy, no systolic septal flattening). Patients were scanned between 3 and 10 days 
post transfusion at baseline, 6 months and 12 months after entering the trial. T2* values and LV 
volumetric data were assessed previously using a CMR viewing and analysis software package 
CMRtools (Cardiovascular imaging solutions, London, UK).[14] LV function was assessed in the 
RCT using an early version of the analysis package in which LV volumes are quantified manually 
using direct surface planimetry, and therefore for consistency we elected to use the same version of 
the software to analyze the RV thus eliminating the need for right sided valve tracking. Care was 
taken to include blood volume below the pulmonary valve. Basal regions with thin, non trabeculated 
muscle were considered atrial and were excluded. Papillary muscles were also excluded from the 
blood pool.[22] Although local blinding to the treatment arm was not possible due to the nature of 
drug administration (oral for deferiprone and subcutaneous for deferoxamine), all remote scan 
analysis performed at the core-lab in London was fully blinded to treatment. Study treatment was 
unblinded on completion of LV and T2* analysis. For the analysis of the RV volumetric data, all data 
sets were anonymized and analyzed in random order using the same analysis package by experienced 
operators blinded to treatment arm and LV response. To assess reproducibility, data-sets with an 
improvement in RVEF ≥ 5% at 12 months were reprocessed blindly. 
 
Statistical analysis 
Continuous variables were compared using a paired t-test. T2* values were log transformed and 
changes expressed as geometric mean with coefficient of variation. Between groups comparison of 
drug effects were assessed using a repeated measurement ANOVA. Statistical significance was set at 
p<0.05. To quantify reproducibility the coefficient of variance (CV) was calculated. 
 
 Results 
Full data on the LA16 study have been published including the patient demographics,[14] but the 
important trial summary findings are repeated here. In the deferiprone group 27 patients completed 
the study; 2 patients withdrew due to adverse events (elevated hepatic enzymes, in one case probably 
due to cytomegalovirus). In the deferoxamine group, 29 patients completed; 1 patient withdrew 
secondary to a reduction in LV function and 2 for personal reasons. The patient groups were well 
matched at baseline for cardiac T2*, LV volumes and function and RV volumes and function (table 
1). Baseline RVEF was within the normal reference range for thalassaemia patients,[19] except for 
one patient in the deferoxamine group (RVEF 1% below the normal range). Patient compliance was 
similar for both groups. Myocardial T2* improved by 18% at 6 months (p<0.001) and 27% at 12 
months (p<0.001) in the deferiprone arm. The LVEF rose by 2.0% from 69.7% at baseline to 71.7% at 
6 months (p<0.001) and by 3.1% to 72.7 at 12 months (p<0.001). With deferoxamine therapy, T2* 
improved by 9% at 6 months (p=0.003) and by 13% at 12 months (p<0.001) but LVEF was 
unchanged being 68.4% at baseline and 68.7 at 6 months (+0.52%, p=0.42) and 68.5 at 12 months 
(+0.32%, p=0.66).  
In the current analysis, the RV mean volumetric and T2* values are detailed in table 2.  To 
summarise, in the deferiprone arm RV end-diastolic volume (EDV) was stable, RV end-systolic 
volume (ESV) decreased significantly from 37.7 to 34.2mL at 12 months (p=0.009); and RVEF 
increased from 69.9% to 72.2% (p=0.001). For the patients on deferoxamine therapy, the changes in 
RV parameters from baseline to 12 months showed no significant difference. Analysis of between 
drugs treatment effects using a repeated measurement ANOVA (table 3) showed significant 
differences favouring deferiprone for the reduction of RV ESV (p=0.009 at 12 months, figure 1) and 
improvement in RVEF (p=0.013 at 12 months, figure 2). Non significant differences between drugs 
were found for RV EDV. With regression analysis, the change in RVEF was found to be inversely 
related to the baseline EF (p<0.001) with a significant difference between drugs favouring deferiprone 
by a mean of 3.5% (95% CI 0.8 to 6.3%; p=0.012). The reduction in RVESV over 12 months was also 
related to the baseline ESV value with borderline significance (p=0.051), and there was a significant 
difference between drugs favouring deferiprone by a mean of 4.5mL more than patients on 
deferoxamine (95% CI 1.2 to 7.8mL; p=0.009). Therefore the patients benefitting most from 
deferiprone treatment are those with the lower baseline values of RVEF. The CV for intra-observer 
study RVEF measurement was 2.4% at baseline and 2.0% at 12 months. There was no relation 
between change in RVEF and change in LVEF (r=0.3, p=0.9). 
 
Discussion 
RV volumetric and functional parameters have been difficult to measure using conventional imaging 
techniques due to the irregular geometry of the RV chamber, the size and quantity of the RV 
trabeculae, and the proximity of the RV to the chest wall which impairs echocardiographic 
assessment. CMR suffers less from these drawbacks because of its inherent 3D nature and high blood 
to myocardium contrast and is therefore considered to be the most accurate and reproducible 
technique for assessing RV volumes and EF.[23,24] Attention to correct definition of the basal slice 
during acquisition and subsequent analysis is however pivotal. The improved confidence of measuring 
RV volumes and function from CMR and other techniques has assisted the understanding the 
importance of the RV in cardiac disease. RVEF is an important predictor of outcome in dilated 
cardiomyopathy, which is both independent of and incremental to LV EF.[15] The predictive value of 
RV function has also been shown in congenital heart disease,[25,26,27] chronic systolic 
dysfunction,[28] and ischemic heart failure,[16,17,29,30] with RVEF being shown to be an 
independent predictor of outcome.[16,17] Accordingly, the effects of myocardial iron loading on RV 
function may be important in thalassaemia patients. 
In the current study, we found a significant improvement in RVEF (increase) and RVESV (reduction) 
with deferiprone therapy. These improvements parallel the previously reported LV response.[14] 
There was no significant increase in RVEDV suggesting loading conditions did not play an important 
role. A flat RV response was seen in the deferoxamine group, which again mirrors LV behaviour. The 
between groups analysis showed superiority for deferiprone over deferoxamine for both the reduction 
in RVESV and the increase in RVEF. The magnitude of improvement in RVEF and reduction in 
RVESV were greater for patients with a higher ESV and lower EF at baseline. Interestingly neither 
LVEF nor RVEF improved significantly in the deferoxamine group despite the improvement in T2*. 
The cause for this difference in functional response is not fully understood, but the explanation may 
lie in the additional effects of deferiprone on restoring normal cardiac mitochondrial function,[31] 
possibly through effects on reducing reactive oxygen species.[32]   
There is little other data relating RV function changes with the iron chelators, but a recently published 
abstract relating to a longitudinal trial of the efficacy of deferasirox in myocardial siderosis,[33] 
showed a significant improvement in myocardial iron levels with an improvement in RVEF at 1 year, 
but no change in LV function at 1,[34] 2,[35] and 3[36] years of follow up. The significance of this 
discrepancy between RV and LV response to deferasirox is not currently clear, though it is possible 
that the RV response is an early signal of myocardial iron clearance as LV compliance and filling 
pressure improves.  
 
Limitations 
Data acquisition for this study was originally designed to assess the change in T2* and LV functional 
parameters in response to therapy. Therefore no RV long axis images were obtained to construct 3-
dimentional models for volumetric analysis, but the requirement for this was removed by using direct 
manual planimetry for quantitative analysis of RV volumes. Pulmonary arterial pressure was not 
systematically measured using echocardiography of the tricuspid regurgitant jet, but here was no 
CMR evidence of raised pulmonary artery pressure in our patients, and pulmonary hypertension is 
rare in well treated thalassaemia major.[37] Direct RV measurement of T2* would have been 
interesting in this population to compare with changes in RV volumes and function, however, it is 
challenging to measure T2* in the thin wall of the RV and this was not attempted in the randomized 
controlled trial. 
 
Conclusions 
This study has shown that RVESV decreased and RVEF improved with deferiprone monotherapy and 
this beneficial response was superior to deferoxamine. RV volumetric and function parameters have 
in the past been neglected when reporting the efficacy of iron chelators for myocardial iron overload, 
and may have independent prognostic importance, as they do in other cardiac conditions with 
impaired cardiac function. 
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Table legends 
Table 1. Baseline values for cardiac volume and function parameters. Values are mean ±SD except for 
T2* where values are geometric mean with CV.  
 
Table 2.  RV volumetric parameters at baseline, 6 and 12 months (mean ±SD) in the 2 treatment arms. 
The T2* values show the geometric mean and CV. The p value reflects the change from baseline to 12 
months. 
 
Table 3.  Between drug effect on  RV volumetric parameters showing a significant difference in RV 
ESV and RVEF favouring deferiprone. 
 
 
 
 
 
Figure legends 
Figure 1. The response in the 2 treatment arms for RVESV showed a significant improvement for 
patients treated with deferiprone, which was not seen with deferoxamine (12 month difference 
between drugs p=0.009). 
 
Figure 2. The response in the 2 treatment arms for RVEF showed a significant improvement for 
patients treated with deferiprone, which was not seen with deferoxamine (12 month difference 
between drugs p=0.013). 
 
 
 
 
Table 1.  
  Deferiprone Deferoxamine p 
No. Patients randomised 28 32   
Age 25.1 ± 3.8 26.6 ± 4.7 0.33 
Male sex (%) 15 (52) 16 (50) 0.99 
Weight (kg) 57.7 ± 7.9 60.6 ± 13.2 0.30 
Cardiac parameters       
Myocardial T2* (ms) 13.0 (32%) 13.3 (30%) 0.77 
LVEDV (mL) 134 ± 32 132 ± 23 0.81 
LVESV (mL) 43 ± 14 41 ± 13 0.51 
LVEF (%) 69.7 ± 5.4 68.4 ± 4.9 0.34 
RVEDV (mL) 122.5 ± 24.9 124.7 ± 27.7 0.75 
RVESV (mL) 37.7 ± 11.7 38.1 ± 12.6 0.90 
RVEF (%) 69.6 ± 5.2  70.0 ± 5.8 0.79 
Biochemical markers       
Liver iron concentration (µg/L) 6.16 ± 6.0 6.32 ± 5.8 0.92 
Serum ferritin (µg/L) 1791 ± 1029 2795 ± 2441 0.039 
Haematology       
Transfusional iron (mL/kg/year) 152 ± 43.4 144 ± 44.4 0.53 
Haemoglobin level (g/L) 105 ± 12.0 113 ± 11.9 0.023 
 
 
 
 
Table 2.   
    Baseline 6 Months 12 Months p 
            
Deferiprone           
  T2*, ms 13.0 (32) 15.4 (38) 16.5 (38) <0.001 
  RVEDV, mL 122.5 ±24.9 123.2 ±26.0 121.3 ±24.9 0.61 
  RVESV, mL 37.7 ±11.7 35.9 ±11.7 34.2 ±11.3 0.009 
  RVSV, mL 84.7 ±16.5 87.3 ±16.5 87.1 ±17.0 0.16 
  RVEF, % 69.9 ±5.2 71.4 ±4.7 72.2 ±5.3 0.001 
            
Deferoxamine           
  T2*, ms 13.3 (30) 14.4 (37) 15 (39) <0.001 
  RVEDV, mL 124.7 ±27.7 124.4 ±26.2 128 ±32.1 0.17 
  RVESV, mL 38.1 ±12.6 37.2 ±12.5 39.1 ±13.0 0.38 
  RVSV, mL 86.7 ±18.0 87.0 ±15.5 88.9 ±21.3 0.25 
  RVEF, % 70.0 ±5.8 70.8 ±5.2 69.9 ±4.6 0.93 
 
 
 
Table 3.   
  Treatment effect   
  Deferiprone-Deferoxamine   
  Mean 95% CI p  
EDV -1.21 -4.44 2.03 0.47 
ESV -1.82 -3.27 -0.37 0.014 
SV 0.64 -2.02 3.31 0.64 
EF 1.16 0.30 2.01 0.008 
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